Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ANIP ANI Pharmaceuticals	$62.56 +0.7%	$64.74	$52.50 ▼ $77.00	$1.36B	0.55	310,620 shs	150,686 shs
GPCR Structure Therapeutics	$21.68 -2.4%	$22.64	$13.22 ▼ $49.91	$1.24B	-1.87	853,335 shs	669,777 shs
TVTX Travere Therapeutics	$14.50 -2.9%	$16.87	$6.80 ▼ $25.29	$1.29B	0.75	1.62 million shs	1.58 million shs
YSB YS Biopharma		$1.25	$0.35 ▼ $1.78	$344.32M	0.51	172,401 shs	63,510 shs

7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ANIP ANI Pharmaceuticals	+0.71%	+0.97%	+3.63%	+0.11%	-2.57%
GPCR Structure Therapeutics	-2.43%	+2.60%	-8.98%	+2.99%	-58.31%
TVTX Travere Therapeutics	-2.95%	-5.35%	-31.25%	-26.51%	+97.55%
YSB YS Biopharma	0.00%	0.00%	0.00%	0.00%	+424.27%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ANIP ANI Pharmaceuticals	4.1678 of 5 stars	3.5	1.0	0.0	3.3	2.5	3.3	1.3
GPCR Structure Therapeutics	2.4273 of 5 stars	3.5	2.0	0.0	0.0	2.8	1.7	0.6
TVTX Travere Therapeutics	2.4722 of 5 stars	4.4	1.0	0.0	0.0	1.9	0.8	0.6
YSB YS Biopharma	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ANIP ANI Pharmaceuticals	3.00	Buy	$80.13	28.08% Upside
GPCR Structure Therapeutics	3.00	Buy	$76.50	252.86% Upside
TVTX Travere Therapeutics	2.87	Moderate Buy	$32.14	121.67% Upside
YSB YS Biopharma	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest YSB, ANIP, TVTX, and GPCR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/11/2025	TVTX Travere Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Buy	$30.00
6/11/2025	TVTX Travere Therapeutics	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$35.00 ➝ $32.00
5/16/2025	TVTX Travere Therapeutics	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
5/16/2025	TVTX Travere Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$30.00 ➝ $30.00
5/12/2025	ANIP ANI Pharmaceuticals	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$86.00 ➝ $86.00
5/12/2025	GPCR Structure Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$80.00 ➝ $75.00
5/2/2025	GPCR Structure Therapeutics	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$60.00
5/2/2025	TVTX Travere Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$30.00 ➝ $30.00
5/2/2025	TVTX Travere Therapeutics	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Hold ➝ Hold	$22.00 ➝ $23.00
4/23/2025	TVTX Travere Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight
4/22/2025	GPCR Structure Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$80.00 ➝ $80.00

(Data available from 6/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ANIP ANI Pharmaceuticals	$674.07M	2.01	$6.93 per share	9.03	$21.13 per share	2.96
GPCR Structure Therapeutics	N/A	N/A	N/A	N/A	$9.77 per share	N/A
TVTX Travere Therapeutics	$273.53M	4.71	N/A	N/A	$2.67 per share	5.43
YSB YS Biopharma	$560.76M	0.00	N/A	N/A	$1.14 per share	0.00

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ANIP ANI Pharmaceuticals	$18.78M	-$1.27	N/A	14.86	N/A	-1.28%	15.87%	6.88%	8/5/2025 (Estimated)
GPCR Structure Therapeutics	-$89.62M	-$0.87	N/A	N/A	N/A	N/A	-16.37%	-15.68%	8/6/2025 (Estimated)
TVTX Travere Therapeutics	-$111.40M	-$2.81	N/A	N/A	N/A	-137.90%	-1,636.87%	-55.95%	7/30/2025 (Estimated)
YSB YS Biopharma	-$21.17M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	N/A

Latest YSB, ANIP, TVTX, and GPCR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/9/2025	Q1 2025	ANIP ANI Pharmaceuticals	$1.37	$1.70	+$0.33	$0.69	$179.75 million	$197.12 million
5/8/2025	Q1 2025	GPCR Structure Therapeutics	-$0.24	-$0.27	-$0.03	-$0.27	N/A	N/A
5/1/2025	Q1 2025	TVTX Travere Therapeutics	-$0.55	-$0.47	+$0.08	-$0.47	$77.44 million	$81.73 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ANIP ANI Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
GPCR Structure Therapeutics	N/A	N/A	N/A	N/A	N/A
TVTX Travere Therapeutics	N/A	N/A	N/A	N/A	N/A
YSB YS Biopharma	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ANIP ANI Pharmaceuticals	1.52	2.74	1.97
GPCR Structure Therapeutics	N/A	27.63	27.63
TVTX Travere Therapeutics	24.96	1.71	1.68
YSB YS Biopharma	0.26	0.94	0.73

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ANIP ANI Pharmaceuticals	76.05%
GPCR Structure Therapeutics	91.78%
TVTX Travere Therapeutics	N/A
YSB YS Biopharma	52.64%

Insider Ownership

Company	Insider Ownership
ANIP ANI Pharmaceuticals	12.70%
GPCR Structure Therapeutics	9.43%
TVTX Travere Therapeutics	4.19%
YSB YS Biopharma	N/A

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ANIP ANI Pharmaceuticals	600	21.66 million	18.36 million	Optionable
GPCR Structure Therapeutics	136	57.34 million	51.86 million	Optionable
TVTX Travere Therapeutics	460	88.81 million	75.12 million	Optionable
YSB YS Biopharma	773	93.06 million	N/A	Not Optionable

YSB, ANIP, TVTX, and GPCR Headlines

Recent News About These Companies

YS Life

October 25, 2024 | yourstory.com

LakeShore Biopharma Co., Ltd.: LakeShore Biopharma Announces Results of Extraordinary General Meeting on Share Consolidation

October 3, 2024 | finanznachrichten.de

LakeShore changes CEO with new executive appointments

September 5, 2024 | thepharmaletter.com

LakeShore Biopharma Co Ltd Ordinary Shares LSB

August 17, 2024 | morningstar.com

LSB LakeShore Biopharma Co., Ltd

July 20, 2024 | seekingalpha.com

Pieris Pharmaceuticals (NASDAQ:PIRS) Stock Quotes, Forecast and News Summary

July 19, 2024 | benzinga.com

YS Biopharma Co., Ltd.: YS Biopharma Announces Name Change to LakeShore Biopharma

May 24, 2024 | finanznachrichten.de

YS Biopharma Announces Name Change to LakeShore Biopharma

May 24, 2024 | prnewswire.com

YS Biopharma Co., Ltd.: YS Biopharma Announces Results of Extraordinary General Meeting

May 22, 2024 | finanznachrichten.de

YS Biopharma Announces Results of Extraordinary General Meeting

May 21, 2024 | prnewswire.com

YS Biopharma to Hold Extraordinary General Meeting on May 21, 2024 and Announces the Appointment of Interim Chief Executive Officer

May 7, 2024 | prnewswire.com

With 80% ownership, YS Biopharma Co., Ltd. (NASDAQ:YS) insiders have a lot riding on the company's future

May 7, 2024 | finance.yahoo.com

YS Biopharma Co., Ltd.: YS Biopharma Receives Additional 180 Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule

April 29, 2024 | finanznachrichten.de

YS Biopharma Receives Additional 180 Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule

April 29, 2024 | prnewswire.com

YS Biopharma Co., Ltd. (NASDAQ:YS) Q3 2024 Earnings Call Transcript

April 22, 2024 | finance.yahoo.com

YS Biopharma Co., Ltd.: YS Biopharma Announces Unaudited Financial Results for the First Nine Months of Fiscal Year 2024

April 19, 2024 | finanznachrichten.de

YS Biopharma Co., Ltd.: YS Biopharma Announces Unaudited Financial Results for the First Nine Months of Fiscal Year 2024

April 19, 2024 | finanznachrichten.de

YS Stock Earnings: YS Biopharma Co Misses EPS, Beats Revenue for Q3 2024

April 19, 2024 | markets.businessinsider.com

YS Biopharma Announces Unaudited Financial Results for the First Nine Months of Fiscal Year 2024

April 19, 2024 | prnewswire.com

YS Biopharma Co., Ltd.: YS Biopharma Granted Phase I Clinical Trial License of Therapeutic Chronic Hepatitis B Virus Vaccine

April 18, 2024 | finanznachrichten.de

New MarketBeat Followers Over Time

Media Sentiment Over Time

YSB, ANIP, TVTX, and GPCR Company Descriptions

ANI Pharmaceuticals NASDAQ:ANIP

$62.56 +0.44 (+0.71%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$62.47 -0.09 (-0.14%)

As of 06/13/2025 04:04 PM Eastern

ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, group purchasing organizations, specialty pharmacies, and hospitals. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota.

Structure Therapeutics NASDAQ:GPCR

$21.68 -0.54 (-2.43%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$21.70 +0.02 (+0.07%)

As of 06/13/2025 05:42 PM Eastern

Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. It is also developing oral small molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073, a biased agonist for apelin receptor, a GPCR that has been implicated in idiopathic pulmonary fibrosis (IPF); and LTSE-2578, an investigational oral small molecule lysophosphatidic acid 1 receptor antagonist for the treatment of IPF and PPF. The company was formerly known as ShouTi Inc. Structure Therapeutics Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.

Travere Therapeutics NASDAQ:TVTX

$14.50 -0.44 (-2.95%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$14.50 +0.01 (+0.03%)

As of 06/13/2025 07:51 PM Eastern

Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones. The company's clinical-stage programs consist of Sparsentan, a novel investigational product candidate, which has been granted Orphan Drug Designation for the treatment of focal segmental glomerulosclerosis in the U.S. and Europe; and Pegtibatinase (TVT-058), a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria. It has a cooperative research and development agreement with National Institutes of Health's National Center for Advancing Translational Sciences and Alagille Syndrome Alliance for the identification of potential small molecule therapeutics for Alagille syndrome. The company was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. Travere Therapeutics, Inc. was incorporated in 2008 and is headquartered in San Diego, California.

YS Biopharma NASDAQ:YSB

YS Biopharma Co., Ltd., a biopharmaceutical company, engages in discovering, developing, manufacturing, and commercializing of vaccines and therapeutic biologics for infectious diseases and cancer. The company develops a proprietary PIKA immunomodulating technology platform and a series of product targeting PIKA rabies vaccine, PIKA recombinant COVID-19 vaccine, and PIKA YS-ON-001. It operates in China, the United States, Singapore, the United Arab Emirates, and the Philippines. The company was founded in 2002 and is based in Beijing, China.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time